<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285115</url>
  </required_header>
  <id_info>
    <org_study_id>B082005</org_study_id>
    <nct_id>NCT01285115</nct_id>
  </id_info>
  <brief_title>The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form</brief_title>
  <official_title>Phase 3 The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form : A Randomized, Double Blind, Parallel-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Health Industry Development Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Health Industry Development Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized, double blinded, Parallel-controlled study, the investigators planned to
      give Gamisoyosan extract, Gamisoyosan extract powder or controlled medication on Anxiety of
      generalized anxiety disorder according to dosage form.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale(HAM-A)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The HAM-A (Hamilton Anxiety Scale) is a widely used interview scale that measures the severity of a patient's anxiety, based on 14 parameters, including anxious mood, tension, fears, insomnia, somatic complaints and behavior at the interview.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory(STAI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The State-Trait Anxiety Inventory (STAI) was initially conceptualized as a research instrument for the study of anxiety in adults. It is a self-report assessment device which includes separate measures of state and trait anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory(BDI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>BDI is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. Each question has a set of at least four possible answer choices, ranging in intensity. When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Checklist-90-Revised(SCL-90R)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Symptom Checklist-90-R (SCL-90-R) is a relatively brief self-report psychometric instrument (questionnaire). It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. It is also used in measuring the progress and outcome of psychiatric and psychological treatments or for research purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Quality of Life Abbreviated(WHOQOL-BREF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Quality of life is used to evaluate the general well-being of individuals and societies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability(HRV)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Heart rate variability (HRV) is a physiological phenomenon where the time interval between heart beats varies. It is measured by the variation in the beat-to-beat interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSWQ</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Penn State Worry Questionaire is a 16-item inventory assess worry and anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSES</measure>
    <time_frame>8 weeks</time_frame>
    <description>The General Self-Efficacy Scale is a 10-item psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSE</measure>
    <time_frame>8 weeks</time_frame>
    <description>Rosenberg Self-Esteem Scale is questionnaire that popular lore recognizes just &quot;high&quot; self-esteem and &quot;low&quot; self-esteem, the Rosenberg Self-Esteem Scale quantify it in more detail, and feature among the most widely used systems for measuring self-esteem.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo; corn flour,</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)
shape, type: extract(brown)
usage, content: adults;three times a day each sack taken before or between meals
dose, standard: for each sack 7.67g
storage : airtight container, stored in room temperature
expiration date : after manufacture 36 month
macufacturing company: KyungBangnShinYak inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gamisoyosan extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>name of product: KyungBangn-Gamisoyosan-x-gwarip
standard code for item : 200005799
shape, type: extract(grayish brown)
usage, content : adults;three times a day , each sack taken before or between meals
dose, standard: 7.67g for each sack
storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gamisoyosan extract powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>name of product: KyungBangn Gamisoyosan
standard code for item: 200005591
shape, type: powder(brown)
usage, content: adults;three times a day each sack taken before or between meals
dose, standard: 7.67g for each sack
storage : airtight container, stored in room temperature
expiration date : after manufacture 36 month
macufacturing company: KyungBangnShinYak inc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.</description>
    <arm_group_label>Placebo; corn flour,</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KyungBangn-Gamisoyosan-x-gwarip</intervention_name>
    <description>AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.</description>
    <arm_group_label>Gamisoyosan extract</arm_group_label>
    <other_name>standard code for item : 200005799</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KyungBangn Gamisoyosan</intervention_name>
    <description>AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.</description>
    <arm_group_label>Gamisoyosan extract powder</arm_group_label>
    <other_name>standard code for item: 200005591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 20-65

          -  (Structured Clinical Interview for DSM-Ⅳ Axis Ⅰ Disorder, SCID-Ⅰ) subjects who meet
             Structured Clinical Interview for DSM-Ⅳ Axis Ⅰ Disorder, SCID-Ⅰof generalized anxiety
             disorder

        Exclusion Criteria:

          -  Currrent or past history of delusions, halucination

          -  Past history of at least one manic episode, hypomanic episode, or mixed episode

          -  Current or past history of alcohol abuse or alcohol dependence history

          -  Taking substances(e.g. antianxiety drugs, antidepressant, antipsychotic drug,
             steroids, female hormonal drug, L-dopa, digitalis, bromide, cyclosporin, disulfiram,
             isoniazid, yohimbine) which might affect symptoms

          -  Medical conditions(e.g. myocardial infarction,brain tumor, multiple sclerosis,
             pancreatic disease, hyperthyroidism, hypothyroidism, Addison disease, Cushing disease,
             rheumarthritis, cancer, CVA, epilepsy, anemia, pituitarium disease, Vit B12 deficiency
             disease, PMS) that might affect symptoms

          -  Current with hepatoma, hepatic cirrhosis, chronic renal failure, congestive heart
             failure

          -  Pregnancy, lactation, women not using medically accepted means of birth control

          -  Considered not apt to carry out clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Chul Jung, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oriental Hospital of Daejon University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oriental Hospital of Daejon University</name>
      <address>
        <city>Daejon</city>
        <state>Choong-Chung-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>January 26, 2011</last_update_submitted>
  <last_update_submitted_qc>January 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>the president of Korea Health Industry Development Institute</name_title>
    <organization>Korea Health Industry Development Institute</organization>
  </responsible_party>
  <keyword>Generalized anxiety disorder</keyword>
  <keyword>Jingji-zhengchong</keyword>
  <keyword>Gamisoyosan</keyword>
  <keyword>anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

